InvestorNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Board Changes

February 4, 2021 10:35:41
Champignon Brands’ (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Chairman, Dr. Roger McIntyre, today announced changes to its board of directors. According to the update, Bill Wilkerson, LL. D. (Hon), appointed to the company’s board of directors on May 22, 2020, and elected its vice-chair on Sept. 14, 2020, after completing his six-month commitment, has retired from the board. “We thank Dr. Wilkerson for the guidance and the expertise that he brought to Champignon,” said Dr. McIntyre. “His sage counsel has served us well and we appreciate his dedication and active participation in preparing Champignon for its successful future.” Joining the Champignon board is Olga M. Cwiek, an experienced and effective practitioner of good governance. Dr. McIntyre continued, “We are very pleased to welcome Ms. Olga Cwiek to our board. She is known for her focus on decision-making modes, governance systems and procedures, the role of board committees, written guidelines for ethics in management including conflicts of interests, harassment, confidentiality, budgeting and guidelines for future acquisitions. Champignon will be well-served with this expertise.” To view the full press release, visit About Champignon Brands Inc. Champignon Brands is focused on the formulation and manufacturing of novel ketamine, anesthetics and adaptogenic delivery platforms for the nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mild traumatic brain injury (“mTBI”) with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.